As anyone who has bitten into a chili pepper knows, its burning spiciness— though irresistible to some — is intolerable to others. Scientists exploring the chili pepper’s effect are using their findings to develop a new drug candidate for many kinds of pain.
Printing whole new organs for transplants sounds like something out of a sci-fi movie, but the real-life budding technology could one day make actual kidneys, livers, hearts and other organs for patients who desperately need them.
A new study of 9- and 10-year-olds finds that those who are more aerobically fit have more fibrous and compact white-matter tracts in the brain than their peers who are less fit.
When investigators applied light-driven stimulation to nerve cells in the brains of mice that had suffered strokes several days earlier, the mice showed significantly greater recovery in motor ability than mice that had experienced strokes but whose brains weren’t stimulated.
Medical researchers have used DNA sequencing to identify a gene variant responsible for causing lupus in a young patient. The development shows that, for the first time, it is feasible for researchers to identify the individual causes of lupus in patients by using DNA sequencing.
Chemical engineers have devised a new implantable tissue scaffold coated with bone growth factors that are released slowly over a few weeks. When applied to bone injuries or defects, the scaffold induces the body to rapidly form new bone that looks and behaves just like the original tissue.
A single factor can reset the immune system of mice to a state likely similar to what it was 500 million years ago. Scientists reactivated expression of an ancient gene in mice, which is not normally expressed in the mammalian immune system, and found that the animals developed a fish-like thymus.
Mice missing two important proteins of the vascular system develop normally and appear healthy in adulthood, as long as they don’t become injured. If they do, their wounds don’t heal properly, a new study shows.
The U.N. health agency says the Ebola outbreak in West Africa has now killed more than 1,200 people. The World Health Organization says the death toll has risen to 1,229 from among the 2,240 reported cases in Guinea, Liberia, Nigeria and Sierra Leone.
It sounds like science fiction, but it seems that bacteria within us– which outnumber our own cells about 100-fold– may very well be affecting both our cravings and moods to get us to eat what they want, and often are driving us toward obesity.
An estimated 55 million to 105 million people in the United States suffer from foodborne illnesses each year, according to the CDC, resulting in costs of $2 to $4 billion annually. What if Twitter could be used to track those cases and more quickly identify the source of the problem?
New research found that receiving antibiotic treatments early in life can increase susceptibility to specific diseases later on. The study helps scientists understand how different antibiotics affect good bacteria.
A genetic variation linked to schizophrenia, bipolar disorder and severe depression wreaks havoc on connections among neurons in the developing brain, a team of researchers reports.
A scary problem lurks beyond the frenzied efforts to keep people from spreading Ebola: No one knows exactly where the virus comes from or how to stop it from seeding new outbreaks.
On this episode of Bioscience Technology This Week, Christina Jakubowski reports on the possibility of making nuts safer to eat for those with allergies. Our second story tackles important questions about which genes may drive antibiotic resistance.
Ever wonder why it’s hard to focus after a bad night’s sleep? Using mice and flashes of light, scientists show that just a few nerve cells in the brain may control the switch between internal thoughts and external distractions.
An investigation into a potentially dangerous blunder at a government lab found that a scientist kept silent about the accident and revealed it only after other employees noticed something fishy.
Links between a number of common respiratory diseases and an increased risk of developing lung cancer have been found in a large pooled analysis of seven studies involving more than 25,000 individuals.
A new study suggests that antibiotic exposure during a critical window of early development disrupts the bacterial landscape of the gut, home to trillions of diverse microbes, and permanently reprograms the body’s metabolism, setting up a predisposition to obesity.
UT Southwestern Medical Center researchers successfully used a new gene editing method to correct a mutation that leads to Duchenne muscular dystrophy (DMD) in a mouse model of the condition. Researchers used a technique called CRISPR/Cas9-mediated genome editing, which can precisely remove a mutation in DNA, allowing the body’s DNA repair mechanisms to replace it with a normal copy of the gene.
It's an eye-catching angle in the story of an experimental treatment for Ebola: The drug comes from tobacco plants that were turned into living pharmaceutical factories. Using plants this way — sometimes called "pharming" — can produce complex and valuable proteins for medicines.
With new advanced techniques developed by the Copenhagen Center for Glycomics at the University of Copenhagen it is possible to study cells in greater detail than ever before. The findings may, in the long term, improve the treatment of high cholesterol.
Children with sensory processing disorder (SPD) have decreased white matter brain connections in sensory regions very different from those with autism, say researchers. Their study is the first to compare, and find critical differences in, brain connectivity in autism versus SPD versus controls.
Gene-based personalized medicine has many possibilities for diagnosis and targeted therapy, but one big bottleneck: the expensive and time-consuming DNA-sequencing process. Now, researchers have found that nanopores in the material molybdenum disulfide (MoS2) could sequence DNA more accurately, quickly and inexpensively than anything yet available.
An Iowa drug developer says it has enough doses of a possible vaccine for the deadly Ebola virus to launch an initial round of human testing. NewLink Genetics Chief Financial Officer Gordon Link says the timing of the trials is uncertain, but the company is receiving help from a number of sources to speed up the process.